Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...

Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines Provided by GlobeNewswire Apr 22, 2025 10:00am.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

Regeneron Pharma Partners With FujiFilm Diosynth To Boost Capacity At $3 Bln Investment April 22, 2025 — 07:38 am EDT Written by RTTNews.com for RTTNews -> ...

Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory (R/R) multiple myeloma (MM). The regulatory body granted accelerated ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) continues to be a solid investment opportunity, and this is just based on its continued EYLEA expansion.That's because it has been able to achieve FDA ...

Regeneron Pharmaceuticals (REGN 1.86%) ... Regeneron could end up being an excellent investment to build your portfolio around since it still has the potential to be a market-beating stock.

Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.

The results fell short of Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of $8.43 per share.

TARRYTOWN, N.Y., April 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. today announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM ...